It's been 9 months of consolidation under todays share price.
Other than the trial in Israel, the spp and the negative news of bisantrene FDA IND trial on hold ... all there is really is hope that the company has a winning strategy.
At this stage that hope is worth 11c - effectively a premium over the SMA200. And well above the 6.6c CR/9.9 opts.
It's probably going to take news to move it far from here although I did expect the difference of a half cent, from 11 to 11.5 not to be any big deal - seems it is.
It's news V's time (patience) now. IMO potentially another investment opportunity. Let's see.
RAC Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)